Corporate News Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP) experienced a 3.62 % decline during the 24‑hour period concluding at 05:17 PM Central Europe on Friday, 23 September 2026. The share price settled at USD 4.02 on major exchanges. The company’s current market capitalization stands at USD 82.9 million, with 19.3 million shares outstanding. Over the past 24 hours, approximately USD 4.1 million worth of shares were traded.
Since the close of the previous month, CRBP’s stock has fallen by 46.64 %. The 200‑day simple moving average sits at USD 8.74, and the 52‑week high of USD 18.11 was recorded on 28 October 2025, while the 52‑week low of USD 4.03 occurred on 22 October 2026.
Latest Corporate Development
Corbus Pharmaceuticals Holdings announced that data from its CRB‑913 Phase 1B Canyon‑1 study will be presented as a poster at Obesity Week® 2026 in National Harbor, Maryland. The presentation, slated for mid‑November, will focus on the efficacy, safety, and tolerability of CRB‑913, an orally delivered, peripherally restricted CB1 inverse agonist designed for obesity treatment. The company reiterated its broader pipeline, which includes an antibody drug conjugate targeting Nectin‑4‑expressing tumors, and underscored its commitment to advancing therapies in both oncology and obesity. No specific numerical results or market expectations were disclosed; the company noted that the upcoming data presentation is subject to typical early‑stage research uncertainties.
Market Context: Peer Performance
| Stock | Ticker | 24‑hr Change | Current Price | Market Cap |
|---|---|---|---|---|
| Merlin | MRLN | –6.67 % | USD 0.88 | USD 99.1 mn |
| Audioeye | AEYE | +2.79 % | USD 7.93 | USD 99.1 mn |
| Coya Therapeutics | COYA | –1.66 % | USD 4.03 | USD 97.1 mn |
| Zevia PBC | ZVIA | +2.46 % | USD 1.25 | USD 96.7 mn |
| Insight Molecular Diagnostic | IMDX | –5.96 % | USD 2.84 | USD 98.8 mn |
Notable Peer Highlights
Merlin (MRLN), an aerospace and defense technology firm, reported plans to hold a webcast and Q&A session on 12 November 2026 to discuss its third‑quarter performance. The event, scheduled for 4:30 p.m. ET, will be available to registered investors and will feature a replay and supporting materials on the company’s investor‑relations website. Merlin’s autonomous flight systems, including the Merlin Pilot, are positioned to support a broad range of military and civilian aircraft, with significant contracts for C‑130J autonomy underscoring its national security relevance.
Audioeye (AEYE) experienced a modest gain of 2.79 %, maintaining a market capitalization of USD 99.1 million.
Coya Therapeutics (COYA) saw a slight decline of 1.66 %, with a market cap of USD 97.1 million.
Zevia PBC (ZVIA) rose by 2.46 %. The company announced a growth‑equity partnership with GP Investments, involving the issuance of convertible preferred shares valued at approximately USD 20 million. This deal is intended to strengthen Zevia’s balance sheet, fund strategic initiatives such as product innovation and expanded distribution, and provide a long‑term collaborative framework, including a board seat and dividend provision. Zevia also projected a more favorable third‑quarter outlook, with higher net sales and a narrower EBITDA range than previously guided.
Insight Molecular Diagnostic (IMDX) declined 5.96 %, with a market cap of USD 98.8 million.
Company Overview
Corbus Pharmaceuticals Holdings, Inc. is a clinical‑stage pharmaceutical company focused on the development and commercialization of novel therapeutic agents for inflammatory and fibrotic diseases. The company operates across Europe, Israel, and Australia, and is listed on the Nasdaq stock exchange. Its pipeline includes innovative therapies such as lenabasum and CRB‑913, targeting a range of conditions from obesity to oncology.
